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Background
Electroporation of DC with mRNA also allows the loading
of these cells with tumor antigens and the functional mod-
ification of the cellular vaccine. To this goal, we provide
three different molecular adjuvants to immature, mono-
cyte derived DCs through electroporation with mRNA
coding for CD40L, CD70 and caTLR4 or so-called TriMix
mRNA.
At our institution, clinical trials in pretreated advanced
melanoma patients are being performed. These patients
are treated with TriMixDC-MEL, a mixture of TriMix-
DC co-electroporated with mRNA encoding a fusion of
DC.LAMP and 1 of 4 melanoma associated antigens
(gp100, tyrosinase, MAGE-C2 or MAGE-A3).
Results
In a pilot clinical trial, 24.106 TriMixDC-MEL cells were
administrated solely by the intradermal (ID) route.
Subsequently, a phase IB was conducted to investigate the
safety of administrating TriMixDC-MEL by the intrave-
nous (IV) and ID-route. ID administration of TriMixDC-
MEL was found to be feasible, safe, effectively stimulating
CD8+ T-cell responses, but did not result in objective
tumor responses. In contrast, the combined ID/IV admin-
istration is associated with distinct but manageable side-
effects and has seemingly superior clinical activity as
compared to DC administered solely ID in patients with
pretreated advanced melanoma. We also investigated the
safety and activity of TriMixDC-MEL combined with ipili-
mumab. The best objective tumor response observed in
this trial (37 evaluable pts) were 6 CR, 6 PR, 7 SD and 16
PD (disease control rate: 51%). All 6 CR and 3 PR are cur-
rently ongoing (respectively after 23, 22, 20, 20, 19, 17, 15,
14, 14 months). This phase II study of TriMixDC-MEL
ID/IV in combination with ipi demonstrates anti-mela-
noma activity in over 50% of the patients with therapy
resistant advanced melanoma.
Conclusion
Further clinical development of TriMixDC-MEL in combi-
nation with immune checkpoint modulators is warranted.
Furthermore, TriMixDC-MEL is currently under evalua-
tion in a randomized phase II trial in the adjuvant setting
following resection of macrometastases.
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